Organogenesis (ORGO) Q3 2024 Earnings Call Transcript
Organogenesis (NASDAQ: ORGO) Q3 2024 Earnings Call Nov 12, 2024, 5:00 p.m. ET ...
Organogenesis provides update on Phase 3 trial of ReNu in knee osteoarthritis
Organogenesis (ORGO) announced the favorable outcome of the interim analysis of its second Phase 3 randomized control trial of ReNu, a ...
Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and ...
Organogenesis Holdings Inc.: Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of ...